Medicare Enrolled
Dr. Syed Zafar, M.D.
Hematology · Fort Myers, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Zafar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zafar? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Zafar
Dr. Syed Zafar is a hematology in Fort Myers, FL, with 18 years in practice. Based on federal Medicare data, Dr. Zafar performed 371,813 Medicare services across 5,771 unique beneficiaries.
Between the years covered by Open Payments, Dr. Zafar received a total of $79,891 from 80 pharmaceutical and/or device companies across 755 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zafar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 4% volume in FL$ $79,891 industry payments
Medicare Practice Summary
Medicare Utilization ↗371,813
Medicare services
Top 4% in FL for hematology
5,771
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~20,656 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 71,200 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 45,630 | $1 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 40,920 | $0 | $2 |
| Nivolumab injection (Opdivo) | 27,080 | $24 | $72 |
| Oxaliplatin chemotherapy injection | 24,900 | $0 | $12 |
| Daratumumab injection (Darzalex) | 18,360 | $38 | $110 |
| Iron sucrose injection (Venofer) | 17,600 | $0 | $5 |
| Iron infusion (Feraheme) | 12,750 | $0 | $4 |
| Paclitaxel chemotherapy injection | 12,270 | $0 | $2 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 11,100 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 10,740 | $19 | $51 |
| Azacitidine chemotherapy injection | 9,200 | $0 | $4 |
| Epoetin alfa injection (Procrit) for anemia | 8,500 | $6 | $23 |
| Dexamethasone injection (steroid) | 7,370 | $0 | $3 |
| Injection, docetaxel, 1 mg | 5,866 | $0 | $7 |
| Immune globulin infusion (Gammagard) | 5,312 | $36 | $108 |
| Anti-nausea injection (Aloxi/palonosetron) | 4,640 | $1 | $28 |
| Complete blood count (CBC) with differential | 3,797 | $8 | $29 |
| Injection, bortezomib, 0.1 mg | 3,417 | $4 | $113 |
| Injection, leucovorin calcium, per 50 mg | 3,101 | $3 | $12 |
| Blood draw (venipuncture) | 2,930 | $8 | $9 |
| Injection, pemetrexed (pemfexy), 10 mg | 2,657 | $56 | $202 |
| Injection, eflapegrastim-xnst, 0.1 mg | 2,508 | $26 | $116 |
| Injection, fluorouracil, 500 mg | 1,917 | $2 | $7 |
| Anti-nausea injection (ondansetron/Zofran) | 1,720 | $0 | $9 |
| Injection, atropine sulfate, 0.01 mg | 1,480 | $0 | $1 |
| Injection of additional new drug or substance into vein | 1,456 | $12 | $61 |
| Office visit, established patient (30-39 min) | 1,453 | $100 | $339 |
| Injection, octreotide, depot form for intramuscular injection, 1 mg | 1,370 | $161 | $515 |
| Administration of chemotherapy into vein, 1 hour or less | 1,196 | $102 | $378 |
| Drug injection, under skin or into muscle | 976 | $11 | $69 |
| Injection, etoposide, 10 mg | 932 | $1 | $18 |
| Office visit, established patient (20-29 min) | 819 | $67 | $239 |
| Injection, carboplatin, 50 mg | 667 | $2 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 428 | $22 | $84 |
| Injection, cisplatin, powder or solution, 10 mg | 420 | $2 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 392 | $50 | $189 |
| Infusion, normal saline solution , 1000 cc | 383 | $2 | $7 |
| Infusion into a vein for hydration, each additional hour | 378 | $10 | $42 |
| Injection, magnesium sulfate, per 500 mg | 308 | $1 | $2 |
| Injection, diphenhydramine hcl, up to 50 mg | 302 | $1 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 299 | $1 | $6 |
| Infusion into a vein for hydration, 31-60 minutes | 278 | $25 | $156 |
| Administration of additional new drug or substance into vein, 1 hour or less | 258 | $51 | $178 |
| Administration of chemotherapy into vein, each additional hour | 257 | $22 | $79 |
| Injection, zoledronic acid, 1 mg | 243 | $7 | $69 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 230 | $58 | $206 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 230 | $133 | $637 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 207 | $16 | $56 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 178 | $17 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 137 | $132 | $562 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 127 | $26 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 118 | $16 | $56 |
| New patient office visit (45-59 min) | 102 | $131 | $453 |
| Administration of additional new drug or substance into vein using push technique | 98 | $45 | $170 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 93 | $1 | $7 |
| Administration of chemotherapy into vein using push technique | 82 | $81 | $303 |
| Injection of drug or substance into vein | 79 | $30 | $156 |
| Red blood count, automated test | 71 | $4 | $10 |
| New patient office visit, complex (60-74 min) | 68 | $169 | $585 |
| Automated urinalysis | 63 | $2 | $8 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 59 | $3 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 44 | $65 | $192 |
| Office visit, established patient, complex (40-54 min) | 32 | $143 | $474 |
| Red blood count automated, with additional calculations | 15 | $5 | $20 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.5% high complexity
91.8% medium
2.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$79,891
Total received (2018-2024)
Avg $11,413/year across 7 years
Top 7% in FL for hematology
80
Companies
755
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$57,256 (71.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,893 (16.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$9,742 (12.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$8,592
2023$9,428
2022$21,599
2021$2,721
2020$2,878
2019$20,534
2018$14,140
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$13,849
Seagen Inc.
$8,714
Janssen Biotech, Inc.
$6,019
E.R. Squibb & Sons, L.L.C.
$5,219
GlaxoSmithKline, LLC.
$4,901
BeiGene USA, Inc.
$4,063
Verastem, Inc.
$3,572
Bayer HealthCare Pharmaceuticals Inc.
$3,480
Celgene Corporation
$3,349
Seattle Genetics, Inc.
$3,061
Karyopharm Therapeutics Inc.
$2,460
NOVARTIS PHARMACEUTICALS CORPORATION
$2,160
Merck Sharp & Dohme LLC
$2,124
Taiho Oncology, Inc.
$1,987
TAIHO ONCOLOGY, INC.
$1,934
MorphoSys, US Inc.
$1,845
BeiGene, Ltd.
$1,512
Novartis Pharmaceuticals Corporation
$988
Bayer Healthcare Pharmaceuticals Inc.
$866
Merck Sharp & Dohme Corporation
$768
PFIZER INC.
$754
ABBVIE INC.
$680
Epizyme, Inc.,
$549
Incyte Corporation
$509
Genentech USA, Inc.
$483
Gilead Sciences, Inc.
$256
Agios Pharmaceuticals, Inc.
$207
Daiichi Sankyo Inc.
$191
Takeda Pharmaceuticals U.S.A., Inc.
$190
Lilly USA, LLC
$187
Adaptive Biotechnologies Corporation
$182
Spectrum Pharmaceuticals Inc.
$179
Exelixis Inc.
$175
GENZYME CORPORATION
$171
Amgen Inc.
$157
NanoString Technologies, Inc.
$125
Regeneron Healthcare Solutions, Inc.
$122
Janssen Pharmaceuticals, Inc
$116
MENARINI SILICON BIOSYSTEMS, INC.
$115
Deciphera Pharmaceuticals Inc.
$109
JAZZ PHARMACEUTICALS INC.
$101
Intuitive Surgical, Inc.
$96
Eisai Inc.
$95
ACELL, INC.
$94
Ipsen Biopharmaceuticals, Inc
$93
Pharmacyclics LLC, An AbbVie Company
$86
Array BioPharma Inc.
$85
ARRAY BIOPHARMA INC
$85
Astellas Pharma US Inc
$74
Intera Oncology, Inc
$69
EMD Serono, Inc.
$57
AbbVie, Inc.
$53
EUSA Pharma (US) LLC
$48
Rigel Pharmaceuticals, Inc.
$40
CSL Behring
$38
AbbVie Inc.
$35
Alnylam Pharmaceuticals Inc.
$30
Dendreon Pharmaceuticals LLC
$25
GE HEALTHCARE
$25
Dexcom, Inc.
$24
PharmaEssentia USA Corporation
$23
Clovis Oncology, Inc.
$23
Pharmacyclics LLC, an AbbVie Company
$23
Immunomedics, Inc.
$22
Kite Pharma, Inc.
$20
Sirtex Medical Inc
$19
TESARO, Inc.
$18
TerSera Therapeutics LLC
$17
SOBI, INC
$17
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$17
CTI BioPharma Corp.
$15
Helsinn Therapeutics (U.S.), Inc.
$13
Global Blood Therapeutics, Inc.
$13
Sun Pharmaceutical Industries Inc.
$13
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
EISAI INC.
$12
ADC Therapeutics America, Inc.
$12
Secura Bio, Inc.
$11
Fortovia Therapeutics, Inc.
$5
Veracyte, Inc.
$4
Top 3 companies account for 35.8% of total payments
Associated products mentioned in payments ›
6 · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · Abraxane · Alecensa · Aliqopa · Avastin · BESREMI · BEVESPI AEROSPHERE · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CAR-T · CEREZYME · CYRAMZA · Cabometyx · Cellsearch · Copiktra · Creon · DARZALEX · Da Vinci Surgical System · Dexcom G6 Transmitter · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · FARXIGA · FRUZAQLA · Farydak · GAUCHER-DISEASE · GAZYVA · GILOTRIF · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INTERA · INVOKANA · Idelvion · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · MYLOTARG · NINLARO · Neulasta · Nplate · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · PADCEV · PIQRAY · PROMACTA · PROSIGNA ASSAY · PROVENGE · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SPRYCEL · SUTENT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Trodelvy · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XIFAXAN · XPOVIO · XTANDI · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (72%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 7% for hematology in FL.
Equivalent to $21 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
15
Per 100K population
1.9
County median income
$73,099
Nearest hospital
PARK ROYAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Zafar is a mixed practice specialist, with above-average Medicare volume (top 4% in FL), and high industry engagement (consulting-driven, top 7%), with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Zafar experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Zafar performed 71,200 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Zafar receive payments from pharmaceutical companies?
Yes. Dr. Zafar received a total of $79,891 from 80 companies across 755 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zafar's costs compare to other hematologys in Fort Myers?
Dr. Zafar's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zafar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Fort Myers
Browse hematologys in Fort Myers ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology